EPIC Program Annual Report 2009-2010 Appendix: Table VIII

Table VIII
Twenty Most Frequently Purchased Drugs*
Rank by Number
of Claims
Drug and StrengthDrug
Type**
Number
of Claims
EPIC
Payments
Rank by
Payment
Top 20 Totals1,896,413 $51,103,622
Percent of Top 20 Drugs to Total Paid Claims 19.59% 15.32%
1 PLAVIX (75 MG) SS 181,987 $16,461,902 1
2 OMEPRAZOLE (20 MG) Gen 145,822 $884,924 73
3 FUROSEMIDE (40 MG) Gen 120,316 $162,930 335
4 AMLODIPINE BESYLATE (5 MG) Gen 115,009 $321,830 190
5 SIMVASTATIN (20 MG) Gen 103,689 $337,175 178
6 NEXIUM (40 MG) SS 100,355 $10,870,410 2
7 ALENDRONATE SODIUM (70 MG) Gen 98,604 $471,405 126
8 SIMVASTATIN (40 MG) Gen 97,186 $356,924 169
9 FUROSEMIDE (20 MG) Gen 95,915 $103,822 487
10 AMLODIPINE BESYLATE (10 MG) Gen 90,192 $262,404 228
11 LIPITOR (10 MG) SS 86,309 $4,838,255 6
12 HYDROCHLOROTHIAZIDE (25 MG) Gen 83,901 $44,500 812
13 METOPROLOL TARTRATE (50 MG) Gen 81,901 $134,061 404
14 SPIRIVA (18MCG) SS 81,414 $6,293,418 4
15 METFORMIN HCL (500 MG) Gen 75,581 $206,830 270
16 LIPITOR (20 MG) SS 74,356 $5,891,217 5
17 METOPROLOL SUCCINATE (50 MG) Gen 71,530 $860,575 78
18 METOPROLOL TARTRATE (25 MG) Gen 69,885 $118,262 449
19 ATENOLOL (50 MG) Gen 62,354 $88,661 527
20 XALATAN (0.005%) SS 60,107 $2,394,117 21

* Table VIII lists the top 20 drugs ranked by number of adjudicated claims for the program year (October 2009-September 2010) as well as the percentage of the total claims they represent for the year.

** Drug Type values are BNMS='Brand Name Multi-Source', Gen='Generic' and SS='Sole Source.'